Eli Lilly to Acquire Centessa Pharmaceuticals, Securing Promising Oral Narcolepsy Drug Candidate ORX750

Eli Lilly has announced its acquisition of Centessa Pharmaceuticals to gain control of ORX750, a promising oral drug candidate for narcolepsy and other sleep disorders.

The deal was prompted by recent positive developments in the field, including successful trials by competitors and favorable FDA signals, which increased the urgency to secure a best-in-class asset.

This acquisition allows Lilly to bolster its neuroscience pipeline and challenge the existing leaders in the multi-billion dollar sleep disorder treatment market.

Eli Lilly has announced a major move in the neuroscience space, agreeing to acquire Centessa Pharmaceuticals to secure its promising pipeline of treatments for sleep-wake disorders.

At the heart of this deal is ORX750, an oral drug candidate that targets the orexin-2 receptor (OX2R). This mechanism is considered a cutting-edge approach for treating narcolepsy and other conditions marked by excessive daytime sleepiness. Centessa has positioned ORX750 as a potential 'best-in-class' treatment, backed by encouraging early-stage clinical data. For Lilly, this is a strategic play to add a new growth pillar to its neuroscience franchise, which already includes treatments for Alzheimer's and migraines.

So, why did this deal happen now? The timing was driven by a convergence of several key factors. First, the entire OX2R agonist drug class has recently gained significant momentum. Competitors like Takeda and Alkermes have seen major successes, including positive late-stage trial results and an FDA Breakthrough Therapy Designation. This series of events transformed the field from 'promising' to 'probable,' creating an arms race among large pharmaceutical companies to secure the most differentiated assets.

Second, Centessa was negotiating from a position of strength, not desperation. The company had successfully raised $250 million in late 2025, giving it a solid financial footing. This, combined with its positive clinical data and a new CEO dedicated to the orexin program, meant Lilly had to make a compelling offer. Centessa wasn't just a target; it was a valuable partner with a credible standalone path.

Finally, Lilly itself was ready to act. The company had been active in M&A, and a recent, smaller acquisition (Ventyx) passed antitrust review smoothly. This precedent gave Lilly confidence that a deal for Centessa, a similarly sized 'tuck-in' acquisition, would likely face minimal regulatory hurdles, ensuring a high 'certainty of closing.'

Ultimately, this acquisition is a calculated bet on the future of sleep medicine. The current market is dominated by older treatments, but OX2R agonists could represent a fundamental shift toward therapies that address the underlying biology of these disorders. By acquiring Centessa, Lilly isn't just buying a drug; it's buying a strategic entry into a multi-billion dollar market on the cusp of a major therapeutic evolution.

Orexin-2 Receptor (OX2R) Agonist: A type of drug that stimulates orexin receptors in the brain, which play a crucial role in promoting and maintaining wakefulness.
Breakthrough Therapy Designation: An FDA process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy.
Tuck-in Acquisition: A type of acquisition where a large company purchases a smaller one to integrate it into one of its existing divisions. These are typically smaller and more strategic than massive mergers.

Eli Lilly to Acquire Centessa Pharmaceuticals, Securing Promising Oral Narcolepsy Drug Candidate ORX750

Eli Lilly has announced its acquisition of Centessa Pharmaceuticals to gain control of ORX750, a promising oral drug candidate for narcolepsy and other sleep disorders.

The deal was prompted by recent positive developments in the field, including successful trials by competitors and favorable FDA signals, which increased the urgency to secure a best-in-class asset.

This acquisition allows Lilly to bolster its neuroscience pipeline and challenge the existing leaders in the multi-billion dollar sleep disorder treatment market.

Eli Lilly has announced a major move in the neuroscience space, agreeing to acquire Centessa Pharmaceuticals to secure its promising pipeline of treatments for sleep-wake disorders.

Orexin-2 Receptor (OX2R) Agonist: A type of drug that stimulates orexin receptors in the brain, which play a crucial role in promoting and maintaining wakefulness.
Breakthrough Therapy Designation: An FDA process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy.
Tuck-in Acquisition: A type of acquisition where a large company purchases a smaller one to integrate it into one of its existing divisions. These are typically smaller and more strategic than massive mergers.